Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5674561 | 0.81 | ALDH1A1 (0.36) | KMT2AALDH1A1LMNACYP2D6TSHR | |
| SCHEMBL5569635 | 0.77 | BCHE (0.43) | KMT2ABCHEALDH1A1LMNATSHR | |
| SCHEMBL11424950 | 0.76 | BCHE (0.40) | KMT2ABCHEALDH1A1LMNATSHR | |
| SCHEMBL5573133 | 0.75 | ALDH1A1 (0.44) | KMT2ABCHEALDH1A1LMNATSHR | |
| SCHEMBL28985430 | 0.74 | BCHE (0.41) | KMT2ABCHEALDH1A1LMNATSHR | |
| SCHEMBL14760440 | 0.72 | ALDH1A1 (0.41) | KMT2ABCHEALDH1A1LMNATSHR | |
| SCHEMBL5998489 | 0.72 | ALDH1A1 (0.36) | KMT2AALDH1A1LMNACYP2D6TSHR | |
| SCHEMBL74973 | 0.69 | L3MBTL1 (0.55) | KMT2ABCHEALDH1A1TSHRMAPT | |
| SCHEMBL16356254 | 0.69 | BCHE (0.41) | KMT2ABCHEALDH1A1LMNAMEN1 | |
| SCHEMBL31241181 | 0.69 | L3MBTL1 (0.55) | KMT2ABCHEALDH1A1TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170114339-A1 | Inactivation Method | THERMO FISHER SCIENTIFIC BALTICS UAB (LT) | 2017-04-27 | — | — | US | claimed |
| EP-1806400-B1 | Inactivation method | FERMENTAS UAB (LT) | 2013-03-13 | — | — | EP | claimed |
| US-20070224611-A1 | Inactivation method | FERMENTAS UAB | 2007-09-27 | — | — | US | claimed |
| EP-1806400-A2 | Inactivation method | Fermentas UAB (LT) | 2007-07-11 | — | — | EP | claimed |
| EP-3186374-A1 | REVERSIBLY INACTIVATED THERMOSTABLE REVERSE TRANSCRIPTASES, COMPOSITIONS AND METHODS FOR USE | Life Technologies Corporation (US) | 2017-07-05 | — | — | EP | disclosed |
| US-20170114339-A1 | Inactivation Method | THERMO FISHER SCIENTIFIC BALTICS UAB (LT) | 2017-04-27 | — | — | US | disclosed |
| US-20160264950-A1 | REVERSIBLY INACTIVATED THERMOSTABLE REVERSE TRANSCRIPTASES, COMPOSITIONS AND METHODS FOR USE | Life Technologies Corporation | 2016-09-15 | — | — | US | disclosed |
| WO-2016033116-A1 | REVERSIBLY INACTIVATED THERMOSTABLE REVERSE TRANSCRIPTASES, COMPOSITIONS AND METHODS FOR USE | Life Technologies Corporation (US) | 2016-03-03 | — | — | WO | disclosed |
| US-9273304-B2 | Inactivation method | THERMO FISHER SCIENTIFIC BALTICS UAB (LT) | 2016-03-01 | — | — | US | disclosed |
| EP-1806400-B1 | Inactivation method | FERMENTAS UAB (LT) | 2013-03-13 | — | — | EP | disclosed |
| US-20070224611-A1 | Inactivation method | FERMENTAS UAB | 2007-09-27 | — | — | US | disclosed |
| EP-1806400-A2 | Inactivation method | Fermentas UAB (LT) | 2007-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070224611-A1 | Inactivation method | TREH, UNG, NOTUM | KMT2A 1982/4885BCHE 15/4885ALDH1A1 183/4885 |
| US-20170114339-A1 | Inactivation Method | TREH, UNG, NOTUM | KMT2A 1982/4885BCHE 15/4885ALDH1A1 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.